Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). (Q40681408)
Jump to navigation
Jump to search
scientific article published on December 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). |
scientific article published on December 2002 |
Statements
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571) (English)
Amie S Corbin
Eric P Stoffregen
Michael W Deininger
Brian J Druker
1 December 2002